Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, announced two-year results from its REDUCE LAP-HF II randomized clinical trial confirming safety and sustained efficacy of the Corvia® Atrial Shunt in properly selected heart failure patients with preserved or mildly reduced ejection fraction.
